Ligand ID: ZD6


Drugbank ID:
DB05294
(Vandetanib)


Indication:
Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.

Get human targets for ZD6 in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'ZD6'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2a5k 3C-LIKE PEPTIDASE
(SARSr-CoV)		5 / 12
GLY B  79
VAL B  77
LEU B  67
VAL B  20
LEU B  87
1.09A21.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2a5k 3C-LIKE PEPTIDASE
(SARSr-CoV)		3 / 3
ALA A   7
GLY A 124
SER B 113
0.86A21.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2acf REPLICASE
POLYPROTEIN 1AB
(SARS-COV
Tor2)		3 / 3
ALA C 220
GLY C 312
SER C 321
0.37A18.55
GOL  C1005 (-4.2A)
GOL  C1005 (-3.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2ahm REPLICASE
POLYPROTEIN 1AB,
HEAVY CHAIN
REPLICASE
POLYPROTEIN 1AB,
LIGHT CHAIN
(SARSr-CoV)		6 / 12
GLY H 118
VAL H 120
LEU D  25
LEU D  64
TYR G  76
ALA G  79
1.41A21.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2amq 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ALA B   7
GLY B 124
SER A 113
0.89A22.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		3 / 3
ALA E 274
GLY E 296
SER F 311
0.78A15.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2fav REPLICASE
POLYPROTEIN 1AB
(PP1AB) (ORF1AB)
(SARSr-CoV)		3 / 3
ALA A  39
GLY A 131
SER A 140
0.42A21.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2op9 REPLICASE
POLYPROTEIN 1AB
(PP1AB, ORF1AB)
3C-LIKE PROTEINASE
(3CL-PRO, 3CLP)
(SARSr-CoV)		3 / 3
ALA A   7
GLY A 124
SER B 113
0.89A21.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		3 / 3
ALA C 325
GLY C  76
SER A 328
0.85A21.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2pwx 3C-LIKE PROTEINASE
(SARS-COV
BJ01)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.13A20.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2q6g REPLICASE
POLYPROTEIN 1AB
(SARS-COV
BJ01)		3 / 3
ALA B   7
GLY B 124
SER A 113
0.89A22.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2qc2 3C-LIKE PROTEINASE
(-)		3 / 3
ALA B   7
GLY B 124
SER A 113
0.88A21.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2qc2 3C-LIKE PROTEINASE
(-)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.13A21.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2vj1 MAIN PROTEINASE
(SARSr-CoV)		3 / 3
ALA A   7
GLY A 124
SER B 113
0.90A20.86
DMS  B1302 ( 4.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2vj1 MAIN PROTEINASE
(SARSr-CoV)		5 / 12
GLY B  79
VAL B  77
LEU B  67
VAL B  20
LEU B  87
1.11A20.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2w2g NSP3
(SARSr-CoV)		3 / 3
ALA A 500
GLY A 494
SER A 652
0.72A21.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2z3d REPLICASE
POLYPROTEIN 1AB
(PP1AB)
(SARSr-CoV)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.05A21.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		2z9j 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ALA A 116
GLY B 302
SER B   1
0.65A21.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		3atw 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLY B  79
VAL B  77
LEU B  67
VAL B  20
LEU B  87
0.98A21.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		3aw1 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ALA A   7
GLY A 124
SER B 113
0.90A21.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
GLY B 486
VAL B 485
LEU B 503
LEU B 456
LEU B 267
1.11A19.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		3ea7 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ALA B   7
GLY B 124
SER A 113
0.85A21.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		3f9f 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ALA B   7
GLY B 124
SER A 113
0.90A21.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		3f9f 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.08A21.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		3f9g 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ALA B   7
GLY B 124
SER A 113
0.90A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		3f9g 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLY B  79
VAL B  77
LEU B  67
VAL B  20
LEU B  87
1.06A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		3m3s 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ALA A   7
GLY A 124
SER B 113
0.89A21.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		3m3t 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.13A22.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		3m3v 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ALA B   7
GLY B 124
SER A 113
0.89A21.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
GLY A 486
VAL A 485
LEU A 503
LEU A 456
LEU A 267
1.07A19.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		4hi3 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.05A21.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		4hi3 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ALA B 298
GLY A 124
SER A 139
0.88A21.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		4mds 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.07A21.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		5b6o 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.13A21.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		5b6o 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
ALA B   7
GLY B 124
SER A 113
0.90A21.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		3 / 3
ALA D 225
GLY D 232
SER D 171
0.81A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		5c8t GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		3 / 3
ALA D 225
GLY D 232
SER D 171
0.86A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		3 / 3
ALA D 225
GLY D 232
SER D 171
0.79A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
LEU A 167
GLY A 170
VAL A 171
LYS A 137
ASP A 197
1.69A18.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
LEU A 272
LEU A 227
LEU A 262
TYR A 239
ASP A 229
1.80A18.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A  11
VAL A  13
LEU A 177
LEU A  32
ALA A 116
1.79A18.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.17A18.15
K1Y  A 404 ( 3.7A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 283
LEU A 268
LEU A 208
VAL A 204
LEU A 286
1.55A18.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		5tl7 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		3 / 3
ALA D  69
GLY D  82
SER D  61
0.80A20.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		3 / 3
ALA C 874
GLY B1028
SER B 701
0.87A13.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
ALA C 874
GLY C 862
SER A 685
0.87A13.34
ALA  C 874 ( 0.0A)
GLY  C 862 ( 0.0A)
SER  A 685 ( 0.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		6 / 12
LEU C 840
GLY C 839
VAL C 718
LEU C 983
LEU C 745
LEU C 948
1.37A13.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
ALA C 658
GLY C 653
SER C 582
0.86A13.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6acg ACE2
(Homo
sapiens)		5 / 12
GLY D 486
VAL D 485
LEU D 503
LEU D 456
LEU D 267
1.09A19.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		3 / 3
ALA C 874
GLY B1028
SER B 701
0.77A12.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		6 / 12
LEU C 840
GLY C 839
VAL C 718
LEU C 745
VAL C 990
ALA C 940
1.55A13.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		3 / 3
ALA C 874
GLY B1028
SER B 701
0.85A13.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6cs2 ACE2
(Homo
sapiens)		6 / 12
LEU D 266
GLY D 268
LEU D 440
LEU D 240
VAL D 244
ALA D 251
1.80A19.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		3 / 3
ALA F 972
GLY E1167
SER E 974
0.88A17.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		6 / 12
LEU D 948
GLY D 946
LEU E 938
LEU D 938
ALA F 944
LEU E 945
1.79A17.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.11A22.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
ALA A 116
GLY A 149
SER A  10
1.19A22.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.11A22.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m18 ACE2
(Homo
sapiens)		5 / 12
GLY D 486
VAL D 485
LEU D 503
LEU D 456
LEU D 267
1.13A18.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		3 / 3
ALA A  39
GLY A 220
SER A 227
0.85A18.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m1d ACE2
(Homo
sapiens)		3 / 3
ALA B 311
GLY B 377
SER B 411
0.74A18.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ALA B   7
GLY B 124
SER D 113
0.90A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.09A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLY D  79
VAL D  77
LEU D  67
VAL D  20
LEU D  87
1.03A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ALA D   7
GLY D 124
SER B 113
0.91A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ALA B 116
GLY B 149
SER B  10
1.18A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLY C  79
VAL C  77
LEU C  67
TYR C  37
LEU C  87
1.37A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ALA A   7
GLY A 124
SER C  10
1.02A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ALA A   7
GLY A 124
SER C 113
0.88A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ALA D   7
GLY D 124
SER B  10
1.02A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ALA C   7
GLY C 124
SER A 113
0.88A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ALA A 116
GLY A 149
SER A  10
1.17A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ALA A 210
GLY A 215
SER A   1
1.39A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLY C  79
VAL C  77
LEU C  67
VAL C  20
LEU C  87
1.12A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLY B  79
VAL B  77
LEU B  67
VAL B  20
LEU B  87
1.00A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
ALA B   7
GLY B 124
SER D  10
1.01A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 12
LEU A 167
GLY A 170
VAL A 171
LYS A 137
ALA A 193
1.43A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.13A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m71 NSP12
(SARS-CoV-2)		3 / 3
ALA A 382
GLY A 327
SER A 343
1.05A16.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m71 NSP12
(SARS-CoV-2)		5 / 12
LEU A 251
LEU A 127
LEU A 178
VAL A 182
TYR A 286
1.49A16.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m71 NSP12
(SARS-CoV-2)		6 / 12
LEU A 437
GLY A 839
LEU A 891
TYR A 420
ALA A 423
LEU A 883
1.78A16.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m71 NSP12
(SARS-CoV-2)		5 / 12
VAL A 737
LEU A 308
LEU A 470
VAL A 473
ASP A 303
1.21A16.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m71 NSP12
(SARS-CoV-2)		5 / 12
LEU A 316
LEU A 207
LEU A 240
ALA A 250
LEU A 186
1.42A16.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m71 NSP12
(SARS-CoV-2)		3 / 3
ALA A 660
GLY A 327
SER A 343
0.98A16.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m71 NSP12
(SARS-CoV-2)		5 / 12
LEU A 186
VAL A 182
LEU A 131
TYR A 238
LEU A 316
1.38A16.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m71 NSP12
(SARS-CoV-2)		5 / 12
LEU A 245
LEU A 186
VAL A 182
TYR A 149
LEU A 127
1.45A16.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6m71 NSP7
(SARS-CoV-2)		5 / 12
LEU C  17
VAL C  16
LEU C  71
VAL C  66
LEU C  56
1.45A17.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6nb7 SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
ALA B 658
GLY B 298
SER B 582
0.90A12.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6nur NSP12
NSP7
(SARSr-CoV)		3 / 3
ALA A 423
GLY A 839
SER C   4
0.73A17.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6vw1 ACE2
(Homo
sapiens)		5 / 12
GLY A 486
VAL A 485
LEU A 503
LEU A 456
LEU A 267
1.13A19.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6vxs NSP3
(SARS-CoV-2)		3 / 3
ALA B  38
GLY B 130
SER B 139
0.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6vxs NSP3
(SARS-CoV-2)		3 / 3
ALA B  39
GLY B  51
SER B  65
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6vxs NSP3
(SARS-CoV-2)		3 / 3
ALA A  38
GLY A 130
SER A 139
0.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6vxs NSP3
(SARS-CoV-2)		3 / 3
ALA A  39
GLY A  51
SER A  65
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6vxs NSP3
(SARS-CoV-2)		5 / 12
GLY A  48
VAL A  49
LEU A  88
VAL A  35
ASP A  22
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		5 / 12
VAL H 211
LEU H 159
VAL H 182
ALA H 136
LEU H 189
1.49A19.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		3 / 3
ALA H 137
GLY H 162
SER L 174
1.04A19.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 12
GLY L  57
VAL L  58
LEU L  73
TYR L  49
LEU L  46
1.71A21.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w61 NSP10
(SARS-CoV-2)		5 / 12
LEU B4365
GLY B4362
VAL B4361
TYR B4329
ALA B4276
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
LEU A6883
GLY A6879
VAL A6882
LEU B4298
LEU A6848
1.64A18.67
None
SAM  A7104 (-3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
LEU A6883
VAL A6882
LEU A7042
LEU B4298
LEU A6848
1.66A18.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.18A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY A  48
VAL A  49
LEU A  88
VAL A  35
ASP A  22
1.51A20.85
AMP  A 201 ( 3.6A)
AMP  A 201 ( 3.7A)
None
None
AMP  A 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		3 / 3
ALA B  39
GLY B  46
SER B  65
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		3 / 3
ALA B  38
GLY B 130
SER B 139
0.78A
MES  B 201 ( 3.4A)
MES  B 201 ( 3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY B  48
LEU B 164
LEU B 160
VAL B 155
ALA B 124
1.60A20.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY A  51
GLU A  64
LEU A  83
ALA A  27
LEU A  88
1.50A20.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		3 / 3
ALA A  39
GLY A  46
SER A  65
1.50A20.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY A  48
VAL A  49
LEU A  88
VAL A  35
ALA A 154
1.66A20.85
AMP  A 201 ( 3.6A)
AMP  A 201 ( 3.7A)
None
None
AMP  A 201 ( 4.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		5 / 12
LEU A  75
GLY A  79
VAL A  96
LEU A  53
TYR A  68
1.63A20.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		5 / 12
LEU A 160
VAL A 155
LEU A  53
VAL A  49
ALA A 129
1.78A20.85
None
AMP  A 201 ( 4.4A)
None
AMP  A 201 ( 3.7A)
AMP  A 201 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY A  48
VAL A  49
LEU A 123
VAL A  36
LEU A 127
1.51A20.85
AMP  A 201 ( 3.6A)
AMP  A 201 ( 3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		5 / 12
LEU B 160
VAL B 155
LEU B  53
VAL B  49
ALA B 129
1.75A20.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY B  48
VAL B  49
LEU B  88
VAL B  35
ASP B  22
1.54A20.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		5 / 12
LEU A  53
GLY A  51
VAL A  49
LEU A 109
LEU A 126
1.73A20.85
None
None
AMP  A 201 ( 3.7A)
None
AMP  A 201 ( 4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		5 / 12
LEU A  53
GLY A  51
VAL A  49
LEU A 160
ALA A 124
1.75A20.85
None
None
AMP  A 201 ( 3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		5 / 12
LEU A  10
GLY B   8
LEU B 140
LEU B 164
VAL B 165
1.73A20.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY A  48
VAL A  49
VAL A  35
ALA A 124
ASP A  22
1.75A20.85
AMP  A 201 ( 3.6A)
AMP  A 201 ( 3.7A)
None
None
AMP  A 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		3 / 3
ALA B  39
GLY B  51
SER B  65
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY A  48
LEU A 164
LEU A 160
VAL A 155
ALA A 124
1.56A20.85
AMP  A 201 ( 3.6A)
None
None
AMP  A 201 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY B  51
GLU B  64
LEU B  83
ALA B  27
LEU B  88
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		5 / 12
LEU B  93
VAL B  36
VAL B 147
ALA B 112
LEU B 127
1.64A20.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		5 / 12
LEU B  53
GLY B  51
VAL B  49
LEU B 160
ALA B 124
1.70A20.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w6y NSP3
(SARS-CoV-2)		3 / 3
ALA A  38
GLY A 130
SER A 139
0.50A
AMP  A 201 ( 3.9A)
AMP  A 201 ( 3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w75 NSP10
(SARS-CoV-2)		5 / 12
LEU B4365
GLY B4362
VAL B4361
TYR B4329
ALA B4276
1.31A16.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
LEU C6883
VAL C6882
LEU C7042
LEU D4298
LEU C6848
1.65A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
LEU A6883
VAL A6882
LEU A7042
LEU B4298
LEU A6848
1.67A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w75 NSP10
(SARS-CoV-2)		5 / 12
LEU D4365
GLY D4362
VAL D4361
TYR D4329
ALA D4276
1.40A16.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w75 NSP16
(SARS-CoV-2)		5 / 12
LEU C6959
LEU C6893
LEU C6892
VAL C6865
ALA C6966
1.79A19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
LEU A6883
GLY A6879
VAL A6882
LEU B4298
LEU A6848
1.69A19.48
None
SAM  A7102 ( 3.4A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
LEU C6883
GLY C6879
VAL C6882
LEU D4298
LEU C6848
1.68A19.48
None
SAM  C7105 ( 3.4A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wcf NSP3
(SARS-CoV-2)		3 / 3
ALA A  39
GLY A  46
SER A  65
1.44A
MES  A 201 ( 4.7A)
MES  A 202 (-4.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wcf NSP3
(SARS-CoV-2)		5 / 12
GLY A  51
GLU A  64
LEU A  83
ALA A  27
LEU A  88
1.46A
MES  A 202 (-3.3A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wcf NSP3
(SARS-CoV-2)		3 / 3
ALA A  38
GLY A 130
SER A 139
0.78A
MES  A 201 (-3.6A)
MES  A 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wcf NSP3
(SARS-CoV-2)		3 / 3
ALA A  39
GLY A  51
SER A  65
1.40A
MES  A 201 ( 4.7A)
MES  A 202 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wen NSP3
(SARS-CoV-2)		5 / 12
GLY A  51
GLU A  64
LEU A  83
ALA A  27
LEU A  88
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wen NSP3
(SARS-CoV-2)		3 / 3
ALA A  39
GLY A  46
SER A  65
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wen NSP3
(SARS-CoV-2)		3 / 3
ALA A  38
GLY A 130
SER A 139
0.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wen NSP3
(SARS-CoV-2)		5 / 12
GLY A  48
LEU A 164
LEU A 160
VAL A 155
ALA A 124
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wen NSP3
(SARS-CoV-2)		3 / 3
ALA A  39
GLY A  51
SER A  65
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wey NSP3
(SARS-CoV-2)		3 / 3
ALA A 243
GLY A 255
SER A 269
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wey NSP3
(SARS-CoV-2)		5 / 12
GLY A 255
GLU A 268
LEU A 287
ALA A 231
LEU A 292
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wey NSP3
(SARS-CoV-2)		3 / 3
ALA A 242
GLY A 334
SER A 343
0.96A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wey NSP3
(SARS-CoV-2)		5 / 12
GLY A 252
VAL A 253
LEU A 292
VAL A 239
ASP A 226
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		3 / 3
ALA D 273
GLY D 295
SER C 310
0.86A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		3 / 3
ALA E 273
GLY E 295
SER F 310
0.87A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		3 / 3
ALA F 273
GLY F 295
SER E 310
0.91A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		3 / 3
ALA A 273
GLY A 295
SER B 310
0.85A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		3 / 3
ALA C 273
GLY C 295
SER D 310
0.88A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		3 / 3
ALA B 273
GLY B 295
SER A 310
0.87A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wjt NSP10
(SARS-CoV-2)		5 / 12
LEU D4365
GLY D4362
VAL D4361
TYR D4329
ALA D4276
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wjt NSP10
(SARS-CoV-2)		5 / 12
LEU B4365
GLY B4362
VAL B4361
TYR B4329
ALA B4276
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wkq NSP10
(SARS-CoV-2)		5 / 12
LEU D4365
GLY D4362
VAL D4361
TYR D4329
ALA D4276
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wkq NSP10
(SARS-CoV-2)		5 / 12
LEU B4365
GLY B4362
VAL B4361
TYR B4329
ALA B4276
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
GLY A 157
LEU A  73
VAL A 142
TYR A 180
LEU A 190
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
GLY B 157
LEU B  73
VAL B 142
TYR B 180
LEU B 190
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
0.95A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ALA C  39
GLY C  51
SER C  65
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ALA C  38
GLY C 130
SER C 139
0.68A
APR  C 201 (-3.4A)
APR  C 201 (-3.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ALA B  39
GLY B  51
SER B  65
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ALA B  38
GLY B 130
SER B 139
0.63A
APR  B 201 (-3.3A)
APR  B 201 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A  51
GLU A  64
LEU A  83
ALA A  27
LEU A  88
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY D  48
LEU D 164
LEU D 160
VAL D 155
ALA D 124
1.48A
APR  D 201 (-3.5A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		6 / 12
GLY B  48
VAL B  49
LEU B  88
VAL B  35
ALA B 124
ASP B  22
1.71A
APR  B 201 (-3.4A)
APR  B 201 (-3.7A)
None
None
None
APR  B 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		6 / 12
GLY A  48
VAL A  49
LEU A  88
VAL A  35
ALA A 124
ASP A  22
1.75A
APR  A 201 (-3.5A)
APR  A 201 (-3.8A)
None
None
None
APR  A 201 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY C  51
GLU C  64
LEU C  83
ALA C  27
LEU C  88
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY C  48
VAL C  49
LEU C 123
VAL C  36
LEU C 127
1.48A
APR  C 201 (-3.5A)
APR  C 201 (-3.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY C  48
VAL C  49
LEU C  88
VAL C  35
ASP C  22
1.44A
APR  C 201 (-3.5A)
APR  C 201 (-3.8A)
None
None
APR  C 201 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ALA D  39
GLY D  51
SER D  65
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY C  48
LEU C 164
LEU C 160
VAL C 155
ALA C 124
1.49A
APR  C 201 (-3.5A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ALA D  38
GLY D 133
SER D 139
0.87A
APR  D 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY B  51
GLU B  64
LEU B  83
ALA B  27
LEU B  88
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		6 / 12
GLY D  48
VAL D  49
LEU D  88
VAL D  35
ALA D 124
ASP D  22
1.75A
APR  D 201 (-3.5A)
APR  D 201 (-3.6A)
None
None
None
APR  D 201 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ALA A  39
GLY A  51
SER A  65
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ALA A  38
GLY A 130
SER A 139
0.62A
APR  A 201 (-3.5A)
APR  A 201 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ALA D  38
GLY D 130
SER D 139
0.67A
APR  D 201 (-3.2A)
APR  D 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY D  51
GLU D  64
LEU D  83
ALA D  27
LEU D  88
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wq3 NSP10
(SARS-CoV-2)		5 / 12
LEU B4365
GLY B4362
VAL B4361
TYR B4329
ALA B4276
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wqd NSP7
(SARS-CoV-2)		5 / 12
VAL A  22
LEU A  13
LEU A  14
VAL A  16
ALA A  65
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wqd NSP7
(SARS-CoV-2)		5 / 12
VAL C  22
LEU C  13
LEU C  14
VAL C  16
ALA C  65
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.09A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
ALA A 116
GLY A 149
SER A  10
1.16A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6y2g REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY B  79
VAL B  77
LEU B  67
VAL B  20
LEU B  87
1.04A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6y2g REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
ALA B   7
GLY B 124
SER A 113
0.87A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A  11
VAL A  13
LEU A 177
LEU A  32
ALA A 116
1.79A17.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.19A17.85
None
None
DMS  A 402 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A 283
LEU A 268
LEU A 208
VAL A 204
LEU A 286
1.55A17.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 12
VAL C  22
LEU C  13
LEU C  14
VAL C  16
ALA C  65
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 12
VAL A  22
LEU A  13
LEU A  14
VAL A  16
ALA A  65
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6yi3 NUCLEOPROTEIN
(SARS-CoV-2)		3 / 3
ALA A  98
GLY A  45
SER A  38
1.28A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		3 / 3
ALA B 141
GLY B 166
SER C 180
1.03A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		3 / 3
ALA L  90
GLY L  47
SER B  25
1.06A
None
1PE  L1603 (-3.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6yla HEAVY CHAIN
(Homo
sapiens)		3 / 3
ALA H  88
GLY H 178
SER H 119
1.03A
None
MLI  H 301 ( 4.4A)
MLI  H 301 (-3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		3 / 3
ALA H 141
GLY H 166
SER L 180
1.01A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		3 / 3
ALA C  90
GLY C  47
SER H  25
1.05A
None
1PE  C 301 (-3.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		3 / 3
ALA H 141
GLY H 166
SER L 180
1.05A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.16A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		3 / 3
ALA B 141
GLY B 166
SER C 180
1.01A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		3 / 3
ALA H 141
GLY H 166
SER L 180
1.01A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.17A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		6 / 12
GLY D  48
VAL D  49
LEU D  88
VAL D  35
ALA D 124
ASP D  22
1.80A
EDO  D 209 ( 4.7A)
EDO  D 209 (-4.6A)
None
None
None
EDO  D 209 ( 3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY E  51
GLU E  64
LEU E  83
ALA E  27
LEU E  88
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		6 / 12
GLY B  48
VAL B  49
LEU B  88
VAL B  35
ALA B 124
ASP B  22
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  51
GLU C  64
LEU C  83
ALA C  27
LEU C  88
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY A  51
GLU A  64
LEU A  83
ALA A  27
LEU A  88
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY A  48
VAL A  49
LEU A 123
VAL A  36
LEU A 127
1.48A
None
None
None
None
EDO  A 202 ( 4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA E  39
GLY E  46
SER E  65
1.42A
None
EPE  E 202 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		6 / 12
GLY A  48
VAL A  49
LEU A  88
VAL A  35
ALA A 124
ASP A  22
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA B  38
GLY B 130
SER B 139
0.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY B  51
GLU B  64
LEU B  83
ALA B  27
LEU B  88
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA D  38
GLY D 130
SER D 139
0.50A
EDO  D 205 (-3.5A)
EDO  D 205 ( 4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA A  38
GLY A 130
SER A 139
0.41A
EDO  A 202 (-3.3A)
EDO  A 202 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA A  39
GLY A  51
SER A  65
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA D  39
GLY D  46
SER D  65
1.43A
None
EDO  D 206 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA A  39
GLY A  46
SER A  65
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA C  38
GLY C 130
SER C 139
0.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA E  38
GLY E 130
SER E 139
0.44A
EPE  E 202 (-3.3A)
EPE  E 202 ( 4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA D  39
GLY D  51
SER D  65
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA E  39
GLY E  51
SER E  65
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY D  51
GLU D  64
LEU D  83
ALA D  27
LEU D  88
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY D  51
GLU D  64
LEU D  83
ALA D  27
LEU D  88
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA D  39
GLY D  51
SER D  65
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		6 / 12
GLY E  48
VAL E  49
LEU E  88
VAL E  35
ALA E 124
ASP E  22
1.74A
APR  E 201 (-3.4A)
APR  E 201 (-3.7A)
None
None
None
APR  E 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY A  51
GLU A  64
LEU A  83
ALA A  27
LEU A  88
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA B  38
GLY B 130
SER B 139
0.69A
APR  B 201 (-3.4A)
APR  B 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY E  51
GLU E  64
LEU E  83
ALA E  27
LEU E  88
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY E  48
VAL E  49
LEU E 123
VAL E  36
LEU E 127
1.46A
APR  E 201 (-3.4A)
APR  E 201 (-3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA A  39
GLY A  51
SER A  65
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY B  51
GLU B  64
LEU B  83
ALA B  27
LEU B  88
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		6 / 12
GLY A  48
VAL A  49
LEU A  88
VAL A  35
ALA A 124
ASP A  22
1.72A
APR  A 201 (-3.4A)
APR  A 201 (-3.7A)
None
None
None
APR  A 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA E  38
GLY E 133
SER E 139
0.89A
APR  E 201 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY A  48
VAL A  49
LEU A 123
VAL A  36
LEU A 127
1.42A
APR  A 201 (-3.4A)
APR  A 201 (-3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA C  38
GLY C 130
SER C 139
0.64A
APR  C 201 (-3.4A)
APR  C 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  48
VAL C  49
LEU C 123
VAL C  36
LEU C 127
1.44A
APR  C 201 (-3.5A)
APR  C 201 (-3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		6 / 12
GLY B  48
VAL B  49
LEU B  88
VAL B  35
ALA B 124
ASP B  22
1.72A
APR  B 201 (-3.5A)
APR  B 201 (-3.7A)
None
None
None
APR  B 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA A  38
GLY A 130
SER A 139
0.70A
APR  A 201 (-3.4A)
APR  A 201 ( 3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY D  48
VAL D  49
LEU D 123
VAL D  36
LEU D 127
1.45A
EDO  D 204 ( 3.4A)
APR  D 201 (-3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  51
GLU C  64
LEU C  83
ALA C  27
LEU C  88
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA C  39
GLY C  51
SER C  65
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA A  38
GLY A 133
SER A 139
0.92A
APR  A 201 (-3.4A)
EDO  A 205 (-3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA D  38
GLY D 130
SER D 139
0.71A
APR  D 201 (-3.3A)
APR  D 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA B  39
GLY B  51
SER B  65
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		6 / 12
GLY D  48
VAL D  49
LEU D  88
VAL D  35
ALA D 124
ASP D  22
1.72A
EDO  D 204 ( 3.4A)
APR  D 201 (-3.7A)
None
None
None
APR  D 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA E  39
GLY E  51
SER E  65
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA E  38
GLY E 130
SER E 139
0.69A
APR  E 201 (-3.3A)
APR  E 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		6 / 12
GLY C  48
VAL C  49
LEU C  88
VAL C  35
ALA C 124
ASP C  22
1.71A
APR  C 201 (-3.5A)
APR  C 201 (-3.6A)
None
None
None
APR  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA C  39
GLY C  51
SER C  65
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY A  51
GLU A  64
LEU A  83
ALA A  27
LEU A  88
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  51
GLU C  64
LEU C  83
ALA C  27
LEU C  88
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA A  38
GLY A 130
SER A 139
0.80A
MES  A 201 (-3.5A)
MES  A 201 (-3.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY B  51
GLU B  64
LEU B  83
ALA B  27
LEU B  88
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		6 / 12
GLY B  48
VAL B  49
LEU B  88
VAL B  35
ALA B 124
ASP B  22
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		6 / 12
GLY C  48
VAL C  49
LEU C  88
VAL C  35
ALA C 124
ASP C  22
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA A  39
GLY A  51
SER A  65
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA B  39
GLY B  51
SER B  65
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA B  38
GLY B 130
SER B 139
0.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA B  39
GLY B  46
SER B  65
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ALA C  38
GLY C 130
SER C 139
0.77A
MES  C 201 (-3.5A)
MES  C 201 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bqy MAIN PROTEASE
(SARS-CoV-2)		3 / 3
ALA A 116
GLY A 149
SER A  10
1.18A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bqy MAIN PROTEASE
(SARS-CoV-2)		5 / 12
GLY A  79
VAL A  77
LEU A  67
TYR A  37
LEU A  87
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bqy MAIN PROTEASE
(SARS-CoV-2)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.06A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7btf NSP12
NSP8
(SARS-CoV-2)		5 / 12
GLY B 113
VAL B 115
LEU A 270
ALA A 383
LEU B 103
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7btf NSP7
(SARS-CoV-2)		5 / 12
VAL C  22
LEU C  13
LEU C  14
VAL C  16
ALA C  65
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7btf NSP12
(SARS-CoV-2)		3 / 3
ALA A 660
GLY A 327
SER A 343
1.00A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7btf NSP12
(SARS-CoV-2)		3 / 3
ALA A 585
GLY A 590
SER A 692
1.08A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7btf NSP12
(SARS-CoV-2)		5 / 12
LEU A 186
VAL A 182
LEU A 131
TYR A 238
LEU A 316
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7btf NSP12
(SARS-CoV-2)		5 / 12
LEU A 251
LEU A 127
LEU A 178
VAL A 182
TYR A 286
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7btf NSP12
NSP7
(SARS-CoV-2)		3 / 3
ALA A 443
GLY A 413
SER C  10
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7btf NSP12
(SARS-CoV-2)		5 / 12
LEU A 245
LEU A 186
VAL A 182
TYR A 149
LEU A 127
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7btf NSP12
(SARS-CoV-2)		3 / 3
ALA A 382
GLY A 327
SER A 343
1.26A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7btf NSP12
(SARS-CoV-2)		5 / 12
GLY A 203
VAL A 204
LEU A 240
LEU A 207
ASP A 235
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7btf NSP12
(SARS-CoV-2)		5 / 12
LEU A 316
LEU A 207
LEU A 240
ALA A 250
LEU A 186
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7btf NSP12
NSP8
(SARS-CoV-2)		3 / 3
ALA B  86
GLY A 510
SER A 518
0.85A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		5 / 12
GLY A  79
VAL A  77
LEU A  67
VAL A  20
LEU A  87
1.15A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
VAL A 737
LEU A 308
LEU A 470
VAL A 473
ASP A 303
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
ALA A 585
GLY A 590
SER A 692
1.10A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
LEU A 251
LEU A 127
LEU A 178
VAL A 182
TYR A 286
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
GLY A 839
LEU A 891
TYR A 420
ALA A 423
LEU A 883
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv1 NSP12
NSP7
(SARS-CoV-2)		3 / 3
ALA A 423
GLY A 839
SER C   4
0.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
ALA A 660
GLY A 327
SER A 343
1.01A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
LEU A 186
VAL A 182
LEU A 131
TYR A 238
LEU A 316
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv1 NSP12
NSP8
(SARS-CoV-2)		3 / 3
ALA B  86
GLY A 510
SER A 518
0.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
LEU A 178
VAL A 182
LEU A 316
LEU A 251
TYR A 175
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
ALA A 382
GLY A 327
SER A 343
1.14A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
GLY A 839
LEU A 891
TYR A 420
ALA A 423
LEU A 883
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv2 NSP12
NSP7
(SARS-CoV-2)		3 / 3
ALA A 443
GLY A 413
SER C  10
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
LEU A 316
LEU A 207
LEU A 240
ALA A 250
LEU A 186
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
LEU A 186
VAL A 182
LEU A 131
TYR A 238
LEU A 316
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv2 NSP12
NSP7
(SARS-CoV-2)		3 / 3
ALA A 423
GLY A 839
SER C   4
0.85A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
ALA A 311
GLY A 352
SER A 318
1.23A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
ALA A 382
GLY A 327
SER A 343
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv2 NSP12
NSP8
(SARS-CoV-2)		5 / 12
GLY B 113
VAL B 115
LEU A 270
ALA A 383
LEU B 103
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
LEU A 251
LEU A 127
LEU A 178
VAL A 182
TYR A 286
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_0
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
VAL A 737
LEU A 308
LEU A 470
VAL A 473
ASP A 303
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		7bv2 NSP12
NSP8
(SARS-CoV-2)		3 / 3
ALA B  86
GLY A 510
SER A 518
0.98A
None